News
-
Texas-based Pulmotect, which is developing an inhaled immune stimulant for the treatment of respiratory diseases, has announced the appointment of Colin Broom as CEO. Broom was most recently CEO of Nabriva Therapeutics and previously served… Read more . . .
-
According to AstraZeneca, the FDA has issued a complete response letter to the company’s NDA for PT010 budesonide/glycopyrronium/formoterol fumarate MDI for the treatment of COPD. AstraZeneca recently announced positive results from the Phase 3 ETHOS… Read more . . .
-
Lannett said that it has signed a US distribution agreement for rights to Respirent Pharmaceuticals’ generic Advair Diskus. The agreement would begin after FDA approval and would continue for 10 years after distribution begins. Lannett… Read more . . .
-
Novartis has announced that its Phase 3 PALLADIUM trial of QMF149 indacaterol acetate/mometasone furoate (IND/MF) delivered via the Breezhaler DPI in patients with uncontrolled asthma met its primary endpoint, demonstrating superior improvement in lung function… Read more . . .
-
Particle engineering company Nanoform has announced that AstraZeneca is performing an evaluation of Nanoform’s Controlled Expansion of Supercritical Solutions (CESS) technology “across a range of AstraZeneca’s proprietary pharmaceutical products.” According to the Nanoform, its technology can… Read more . . .
-
Noveome Biotherapeutics said that it has initiated a Phase 1 safety trial of its ST266 secretome delivered intranasally in patients with intraocular hypertension. The study will use a device from SipNose designed to deliver drugs… Read more . . .
-
Currax Pharmaceuticals has acquired US, Canadian, and Mexican rights to Onzetra Xsail intranasal dry powder sumatriptan from OptiNose, which announced that the license agreement includes a $4.8 million upfront payment, plus a 10% royalty on net… Read more . . .
-
Dance Biopharm has announced a name change, saying that the company will now be known as Aerami Therapeutics. The company, which is developing the Dance 501 insulin SMI, said that it is also moving its… Read more . . .
-
The Australian government has awarded Victoria-based Lachesis Biosciences AUS$438,000 for commercialization of the company’s rivastigmine nasal spray for the treatment of dementia in patients with Alzheimer’s Disease. The Accelerating Commercialisation grant is designed to”help businesses turn… Read more . . .
-
Device maker H&T Presspart has officially opened a new injection molding facility known as “Fenix” in Tarragona, Spain, the company said. The plant manufactures MDI actuators and other delivery device components. H&T Presspart Tarragona Managing Directors… Read more . . .
Upcoming Events
Sponsored by Intertek
Want information about upcoming OINDP-related events delivered directly to your inbox? click here
July 13-July 16: 2026 ISAM Congress, Taipei, Taiwan
September 15-September 18: DDL New Researcher Network Summer Event, London, UK
September 16-September 17: IPAC-RS 2026 Nasal Innovation Forum, Jersey City, NJ, USA
September 24-September 25: Inhaled & Nasal Biologics | DNA Forum, Cambridge, UK
October 14-October 15: Advancing Bioequivalence Frameworks for Inhalation and Nasal Drug Products: Optimizing In Vitro, In Vivo, and In Silico Methods, Rockville, MD, USA